Abeona Therapeutics Inc Watch

from 8-K 21 pages Supplement to the Loan and Security Agreement Dated as of January 8, 2024 Among Abeona Therapeutics Inc. (“Company”), Macrochem Corporation and Abeona Therapeutics LLC (Together With Company, Each, Individually, a “Borrower”, and Collectively, “Borrower”) Avenue Venture Opportunities Fund, L.P. II, L.P., a Delaware Limited Partnership (“Avenue 2”), as a Lender and Avenue Venture Opportunities Fund, L.P., a Delaware Limited Partnership

from 8-K 37 pages Borrower, Lenders and Agent Anticipate Entering Into One or More Transactions Pursuant to Which Each Lender Agrees to Make Available to Borrower a Loan Facility Governed by the Terms and Conditions Set Forth in This Document and One or More Supplements Executed by Borrower, Lenders and Agent Which Incorporate This Document by Reference. Each Supplement Constitutes a Supplement to and Forms Part of This Document, and Will Be Read and Construed as One With This Document, So That This Document and the Supplement Constitute a Single Agreement Between the Parties (Collectively Referred to as This “Agreement”). Accordingly, the Parties Agree as Follows: Article 1 - Interpretation 1.1 Definitions. the Terms Defined in Article 11 and in the Supplement Will Have the Meanings Therein Specified for Purposes of This Agreement. 1.2 Inconsistency. in the Event of Any Inconsistency Between the Provisions of Any Supplement and This Document, the Provisions of the Supplement Will Be Controlling for the Purpose of All Relevant Transactions. Article 2 - The Commitment and Loans